增殖细胞核抗原对局部晚期宫颈癌新辅助化疗敏感性的预测价值  

The predict value of proliferating cell nuclear antigen on the chemotherapeutical sensitivity in patients with locally advanced cervical cancer

作　　者：杨红文[1] 陈忠东[1] 周波[1] 秦永喜[1] 赵强[2] 马亦良[1] 

机构地区：[1]湖南衡阳南华大学第一附属医院妇产科,421001 [2]湖南衡阳南华大学第一附属医院病理科,421001

出　　处：《中国妇产科临床杂志》2010年第2期92-94,共3页Chinese Journal of Clinical Obstetrics and Gynecology

摘　　要：目的探讨增殖细胞核抗原作为评价局部晚期宫颈癌新辅助化疗敏感性指标的可行性。方法收集2007年1月至2007年9月南华大学第一附属医院妇产科收治的49例局部晚期宫颈癌患者新辅助化疗前后标本组织,采用免疫组织化学技术检测癌组织中增殖细胞核抗原的表达。结果49例局部晚期宫颈癌患者经新辅助化疗治疗2周后评价临床疗效,临床有效(CR+PR)率为79.6%(39/49)。新辅助化疗有效组化疗前宫颈癌组织中PCNA阳性细胞数比率明显高于无效组(P<0.05)。结论增殖细胞核抗原(PCNA)是判定局部晚期宫颈癌化疗敏感性的重要指标。Objective To investigate the feasibility of proliferating cell nuclear antigen （PCNA） as an sensitive maker of neoadjuvant chemotherapy in patients with locally advanced cervical cancer.Methods Data of 49 patients with locally advanced cervical cancer who received neoadjuvant chemotherapy in the First Affiliated Hospital of Nanhua University from January 2007 to September 2007 were analyzed retrospectively. Expression of PCNA in cervical tissues before and after neoadjuvant chemotherapy were examined by immunohistochemical staining. The clinical therapeutic effect was evaluated after two weeks of neoadjuvant chemotherapy and patients were than divided into response group and no- response group.Results The clinical effective rate （CR＋PR） was 79.6% （39/49）, the operation rate after neoadjuvant chemotherapy was 85.7%（42/49）. Expression of PCNA in response group was significant higher than that in no- response group before neoadjuvant chemotherapy（P〈0.05）.Conclusions PCNA is an important maker in assessing chemotherapeutical sensitivity in locally advanced cervical cancer patients.

关 键 词：宫颈肿瘤 新辅助化疗 增殖细胞核抗原 疗效评价 

分 类 号：R737.33[医药卫生—肿瘤]